Beverly Hills Private Wealth LLC Buys 480 Shares of Zoetis Inc. (NYSE:ZTS)

Beverly Hills Private Wealth LLC lifted its position in Zoetis Inc. (NYSE:ZTS) by 7.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,705 shares of the company’s stock after acquiring an additional 480 shares during the quarter. Beverly Hills Private Wealth LLC’s holdings in Zoetis were worth $1,092,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. Bearing Point Capital LLC purchased a new stake in shares of Zoetis during the fourth quarter valued at $233,000. BLI Banque de Luxembourg Investments purchased a new stake in shares of Zoetis in the fourth quarter valued at approximately $45,033,000. Ameriprise Financial Inc. grew its stake in Zoetis by 5.2% in the fourth quarter. Ameriprise Financial Inc. now owns 3,215,753 shares of the company’s stock worth $523,500,000 after purchasing an additional 159,382 shares in the last quarter. Alpha Family Trust increased its holdings in Zoetis by 200.0% during the 4th quarter. Alpha Family Trust now owns 3,270 shares of the company’s stock worth $533,000 after purchasing an additional 2,180 shares during the period. Finally, Alteri Wealth LLC bought a new stake in Zoetis during the 4th quarter valued at $544,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Insiders Place Their Bets

In other news, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now owns 11,245 shares of the company’s stock, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the transaction, the executive vice president now directly owns 15,781 shares in the company, valued at approximately $2,682,770. This trade represents a 2.02 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,862 shares of company stock valued at $312,254. Insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on ZTS shares. StockNews.com upgraded Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Piper Sandler increased their price objective on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a report on Thursday, February 27th. Morgan Stanley lowered their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. Barclays boosted their price target on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Finally, Stifel Nicolaus cut their price objective on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating on the stock in a research note on Monday, April 14th. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, Zoetis has an average rating of “Buy” and a consensus target price of $214.40.

Zoetis Stock Performance

ZTS opened at $157.43 on Friday. The company has a market cap of $70.24 billion, a price-to-earnings ratio of 28.78, a PEG ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33. The firm’s fifty day simple moving average is $158.31 and its two-hundred day simple moving average is $167.22. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company had revenue of $2.32 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Equities analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.27%. Zoetis’s payout ratio is 36.56%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.